A number of other equities research analysts have also commented on AIMT. Wedbush reissued an outperform rating and set a $42.00 price objective on shares of Aimmune Therapeutics in a report on Monday, June 13th. Zacks Investment Research raised shares of Aimmune Therapeutics from a sell rating to a hold rating in a report on Friday, August 26th. Piper Jaffray Cos. reissued an overweight rating and set a $38.00 price objective on shares of Aimmune Therapeutics in a report on Tuesday, June 14th. Finally, Credit Suisse Group AG reissued a buy rating and set a $35.00 price objective on shares of Aimmune Therapeutics in a report on Friday, August 19th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $32.20.
Aimmune Therapeutics (NASDAQ:AIMT) opened at 14.14 on Monday. Aimmune Therapeutics has a 12 month low of $9.77 and a 12 month high of $23.16. The stock’s market capitalization is $597.47 million. The company’s 50-day moving average is $15.02 and its 200-day moving average is $13.62.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings data on Wednesday, August 10th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.01. Equities analysts anticipate that Aimmune Therapeutics will post ($1.75) earnings per share for the current year.
In other Aimmune Therapeutics news, insider Mary M. Rozenman sold 30,000 shares of the company’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $16.80, for a total transaction of $504,000.00. Following the transaction, the insider now directly owns 30,000 shares in the company, valued at approximately $504,000. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 24.56% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Metropolitan Life Insurance Co. NY increased its position in Aimmune Therapeutics by 9.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 9,617 shares of the company’s stock worth $130,000 after buying an additional 797 shares during the last quarter. Emerald Acquisition Ltd. acquired a new position in Aimmune Therapeutics during the second quarter worth about $154,000. American International Group Inc. increased its position in Aimmune Therapeutics by 135.7% in the second quarter. American International Group Inc. now owns 15,131 shares of the company’s stock worth $164,000 after buying an additional 8,711 shares during the last quarter. Nationwide Fund Advisors increased its position in Aimmune Therapeutics by 127.7% in the second quarter. Nationwide Fund Advisors now owns 16,929 shares of the company’s stock worth $183,000 after buying an additional 9,495 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new position in Aimmune Therapeutics during the second quarter worth about $186,000. Institutional investors own 68.87% of the company’s stock.
About Aimmune Therapeutics
Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.